Module for VES-HI Mobilities

12 entries found

VES-HI 030-032 - VHIR - Leuven Area Health Tech Transfer - Leuven (BEL)

The visit to the Leuven health innovation ecosystem, which will take place from 26 to 28 November 2024 with the teams of KU Leuven Research & Development (LRD), members of the EUHA platform, has a triple purpose: on the one hand, to acquire knowledge and experiences on new processes for our Department of Innovation and Business Development, to establish strategic alliances with the leading centers that we will visit, reinforcing our connection with reference innovation platforms at a global level, and on the other hand, to acquire new knowledge for the design of the new Innovation Hub of the Vall d'Hebron Research Institute (VHIR). This stay will allow us to get to know reference centers such as the LRD, UZ Leuven, and the CD3 and AstriVax incubators, as well as the Health House, a leading space in technological solutions in health.  Our objective is to learn from the best international practices and apply this knowledge both in the creation of the new hub and in the optimization of technology transfer in the VHIR. In relation to the Innovation Hub, this visit will allow us to acquire essential knowledge about the management of innovation infrastructures, the dynamization of multidisciplinary teams and the integration of networks, talents and resources. Learning from these models, which have proven to be successful in Leuven, will be key to developing a hub that acts as a driver and catalyst for biomedical innovation. In addition, the visit will allow us to study how they foster the incubation of startups and the scaling of innovative projects, as well as public-private collaborations that favor the transfer of knowledge and solutions to the market.

VES-HI 028 - CRG - EU-LIFE Community Meeting at CeMM - Vienna (OST)

As the Business Development and Intellectual Property (IP) Manager at CRG's Technology & Business Development Office (TBDO), I represented CRG in the EU-LIFE Community Meeting in April 2024. EU-LIFE, an alliance of leading European life sciences research institutes, enhances research quality and impact across Europe through policy advocacy, collaboration, and the development of best practices. As a dedicated member institution, CRG actively contributes to and benefits from EU-LIFE's initiatives, and the annual Community Meeting provides essential opportunities for face-to-face collaboration within Working Groups and with strategic leaders. My role in the TT Working Group involves licensing, and spin-off creation. The meeting was held at CeMM in Vienna, -, an esteemed center for molecular medicine -also an EU-Life. The meeting was held at CeMM in Vienna, -, an esteemed center for molecular medicine -also an EU-Life institutions on IP management, licensing, and spin-off creation. The meeting was held at CeMM in Vienna, -, an esteemed center for molecular medicine -also an EU-Life member institution as CRG- from April 24 to April 26, 2024, which included working sessions, the main Community Meeting including designated two afternoons for TT Working group, and a full day EU-LIFE Utopia Conference on AI in biomedicine . As a subtancial presence of TT professionals were present, the conference sparked a fruitful discussion on TT aspects of AI assets developed at public research institutuions.

VES-HI 023 - CRG - Milner Therapeutics Symposium 2024 - Cambridge (UK)

As part of my role as Industry and Innovation Manager, I attended the Milner Therapeutics Symposium (MTS) 2024, the key, yearly networking event of the Milner Therapeutics Institute (MTI), which is located at the University of Cambridge, UK. It is a collaborative hub, opened in 2015 for advancing therapeutic discovery, by focusing on translating research into new treatments. It does so by bringing together a community of academia, industry, and investors to accelerate the development of new medicines. Over these years, they have built various initiatives aimed at establishing research infrastructure, incubating and accelerating spin-offs, and increasing collaboration between academics and industry, within Cambridge and the local area. Regarding the latter, they have built the Milner Therapeutics Consortium (MTC) which consists of 3 academic centres (Univ. Of Cambridge, Wellcome Sanger Institute and the Babraham Institute) and 10 pharmaceutical companies, including AstraZeneca, Johnson & Johnson and Pfizer. Within this consortium they have agreements in place to streamline interactions between academic researchers and industry partners facilitating the execution of pre-competitive research collaborations between, and they run regular events to facilitate these interactions. One such event is the MTS and it took place on the 2nd of July 2024, at a conference venue in the wider Univ. Of Cambridge Campus. I attended (i) as a representative of an affiliate member and (ii) to learn from a successful initiative aimed to stimulate public-private partnership, a main focus of my role at the CRG.

VES-HI 021 - IBEC - World Medical Innovation Forum (a BIOCAT Mission) - Boston (USA)

The trip is part of a Biocat mission. The trip includes attendance at the World Medical Innovation Forum. It also includes visits to pharmaceutical companies based in Boston, a business accelerator and a research support foundation. The World Medical Innovation Forum brings together global leaders to address the latest opportunities and challenges in the investment landscape, key technological developments, manufacturing and regulatory barriers. New ideas on the future of patient care will be discussed. Attending the Forum not only allows you to learn first-hand about this need, but also allows you to talk to these doctors and present IBEC proposals that can respond to these needs. In addition, one of the documents that will be presented is the survey promoted by this hospital and in which thousands of doctors have participated, identifying the 10 medical needs worldwide. This Forum will also feature companies (their CEOs) who will present their approach to generating new solutions to the challenges of achieving global health. This is an opportunity to show them how IBEC's developments or capabilities can be complementary. In addition to attending the Forum, this mission organized by Biocat includes a visit to some pharmaceutical companies based in Boston to whom we will be able to present IBEC, our capabilities and projects. A visit to a foundation that finances research projects in the form of an incubator is also planned because in addition to funding, they provide laboratory space to develop the project. IBEC is interested in this type of proposal because we can present a project that takes advantage of this initiative to develop the project in a framework of unparalleled opportunities.  Finally, a visit to an accelerator where companies can develop their projects, starting with a place in a small office and which can host the development of this company until it occupies an entire laboratory, is also planned. IBEC is interested